Akynzeo (Fosnetupitant and Palonosetron) and Diltiazem 12-Hour Sustained-Release Capsules
Determining the interaction of Akynzeo (Fosnetupitant and Palonosetron) and Diltiazem 12-Hour Sustained-Release Capsules and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:After a single dose of fosnetupitant, blood levels and effects of dilTIAZem may be increased for approximately six days. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with netupitant or its prodrug, fosnetupitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by netupitant and its desmethyl metabolite. When a single 7.5 mg oral dose of midazolam, a CYP450 3A4 probe substrate, was administered with netupitant 300 mg, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 36% and 126%, respectively. When a 500 mg dose of erythromycin, another CYP450 3A4 substrate, was coadministered with netupitant 300 mg, the mean Cmax and AUC of erythromycin were increased by 92% and 56%, respectively, although the systemic exposure of erythromycin was highly variable.
MANAGEMENT: Caution is advised when netupitant or fosnetupitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever netupitant or fosnetupitant is added to or withdrawn from therapy. The inhibitory effect on CYP450 3A4 can last for 6 days after administration of a single dose of netupitant or fosnetupitant.
- "Product Information. Akynzeo for Injection (fosnetupitant-palonosetron)." Helsinn Therapeutics Inc, Woodbridge Township, NJ.
- "Product Information. Akynzeo (netupitant-palonosetron)." Eisai Inc, Woodcliff Lake, NJ.
Generic Name: fosnetupitant / palonosetron
Brand name: Akynzeo for injection
Synonyms: Fosnetupitant and palonosetron (injection), Fosnetupitant and Palonosetron
Generic Name: diltiazem
Brand name: Cardizem, Cartia XT, Dilacor XR, Dilt-CD, Diltia XT, Dilt-XR, Diltzac, Matzim LA, Taztia XT, Tiazac, Cardizem CD, Tiazac, Cardizem LA, Tiazac Extended Release Capsules
Synonyms: Diltiazem
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem CD
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem Extended Release Tablets
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem Hydrochloride
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem Injection
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem Intravenous
- Akynzeo (Fosnetupitant and Palonosetron)-Diltiazem Long-Acting Capsules
- Diltiazem 12-Hour Sustained-Release Capsules-Akynzeo (Netupitant and Palonosetron)
- Diltiazem 12-Hour Sustained-Release Capsules-Akynzeo for injection
- Diltiazem 12-Hour Sustained-Release Capsules-Akynzeo Intravenous
- Diltiazem 12-Hour Sustained-Release Capsules-Ala Hist IR
- Diltiazem 12-Hour Sustained-Release Capsules-Ala Hist PE
- Diltiazem 12-Hour Sustained-Release Capsules-Ala Quin Cream